[1] T. Asselah, D. Durantel, E. Pasmant, G. Lau, and R.F. Schinazi, COVID-19: Discovery, diagnostics and drug development. J Hepatol 74 (2021) 168-184.http://dx.doi.org/10.1016/j.jhep.2020.09.031
[2] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395 (2020) 497-506.http://dx.doi.org/10.1016/s0140-6736(20)30183-5
[3] M. Ackermann, S.E. Verleden, M. Kuehnel, A. Haverich, T. Welte, F. Laenger, et al., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 383 (2020) 120-128.http://dx.doi.org/10.1056/NEJMoa2015432
[4] S.E. Fox, A. Akmatbekov, J.L. Harbert, G. Li, J. Quincy Brown, and R.S. Vander Heide, Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. The Lancet Respiratory Medicine 8 (2020) 681-686.http://dx.doi.org/10.1016/s2213-2600(20)30243-5
[5] C. Magro, J.J. Mulvey, D. Berlin, G. Nuovo, S. Salvatore, J. Harp, et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 220 (2020) 1-13.http://dx.doi.org/10.1016/j.trsl.2020.04.007
[6] Y. Ding, H. Wang, H. Shen, Z. Li, J. Geng, H. Han, et al., The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 200 (2003) 282-9.http://dx.doi.org/10.1002/path.1440
[7] J.M. Nicholls, L.L.M. Poon, K.C. Lee, W.F. Ng, S.T. Lai, C.Y. Leung, et al., Lung pathology of fatal severe acute respiratory syndrome. The Lancet 361 (2003) 1773-1778.http://dx.doi.org/10.1016/s0140-6736(03)13413-7
[8] D.L. Ng, F. Al Hosani, M.K. Keating, S.I. Gerber, T.L. Jones, M.G. Metcalfe, et al., Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am J Pathol 186 (2016) 652-8.http://dx.doi.org/10.1016/j.ajpath.2015.10.024
[9] N. Tang, H. Bai, X. Chen, J. Gong, D. Li, and Z. Sun, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18 (2020) 1094-1099.http://dx.doi.org/10.1111/jth.14817
[10] L. Ayerbe, C. Risco, and S. Ayis, The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis 50 (2020) 298-301.http://dx.doi.org/10.1007/s11239-020-02162-z
[11] A.S.o. hematology. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions [EB/OL]. (2021). https://www.hematology.org/%20covid-19/covid-19-and-vte-anticoagulation. [12 April, 2021]
[12] N.I.o. Health. COVID-19 Treatment Guidelines [EB/OL]. (2021). https://www.covid19treatmentguidelines.nih.gov./antithrombotic-therapy/. [12 April, 2021]
[13] N.H.C.o.t.P.s.R.o. China. Diagnosis and Treatment Protocol for COVID-19 Patients(Trial Version 8) [EB/OL]. (2020). http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml. [19 August, 2020]
[14] A.D.T. Force, V.M. Ranieri, G.D. Rubenfeld, B.T. Thompson, N.D. Ferguson, E. Caldwell, et al., Acute respiratory distress syndrome: the Berlin Definition. JAMA 307 (2012) 2526-33.http://dx.doi.org/10.1001/jama.2012.5669
[15] W.H.O. (2020), Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. . (2020)
[16] P.C. Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 46 (2011) 399-424.http://dx.doi.org/10.1080/00273171.2011.568786
[17] M.M.v.d.E. W S Lim, R Laing, W G Boersma, N Karalus, G I Town, S A Lewis, J T Macfarlane, Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003).http://dx.doi.org/10.1136/thorax.58.5.377
[18] O. Kuss, M. Blettner, and J. Borgermann, Propensity Score: an Alternative Method of Analyzing Treatment Effects. Dtsch Arztebl Int 113 (2016) 597-603.http://dx.doi.org/10.3238/arztebl.2016.0597
[19] S.S.a.C.K.O.B.O.T.S.O.C.O.A.O.T.S.A.S.C.O.T.I.S.O.T.A. HAEMOSTASIS, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis (2004).http://dx.doi.org/10.1111/j.1538-7836.2005.01204.x
[20] M.N. Levine, G. Raskob, and J. Hirsh, Hemorrhagic complications of long-term anticoagulant therapy. Chest 95 (1989) 26S-36S.http://dx.doi.org/10.1378/chest.95.2_supplement.26s
[21] J. Thachil, N. Tang, S. Gando, A. Falanga, M. Cattaneo, M. Levi, et al., ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 18 (2020) 1023-1026.http://dx.doi.org/10.1111/jth.14810
[22] I. AM Neill, RWeir,RAnderson,AChereshsky,M J Epton,RJackson, M Schousboe,CFrampton,SHutton,STChambers,GITown, Community acquired pneumonia: aetiologyand usefulness ofseveritycriteriaon admission. Thorax (1996).http://dx.doi.org/10.1136/thx.51.10.1010
[23] M.D. LORRAINE B. WARE, AND MICHAEL A. MATTHAY, M.D., The acute respiratory distress syndrome. N Engl J Med (2000).http://dx.doi.org/10.1056/NEJM200005043421806
[24] E.D. Riviello, W. Kiviri, T. Twagirumugabe, A. Mueller, V.M. Banner-Goodspeed, L. Officer, et al., Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. Am J Respir Crit Care Med 193 (2016) 52-9.http://dx.doi.org/10.1164/rccm.201503-0584OC
[25] M. Singer, C.S. Deutschman, C.W. Seymour, M. Shankar-Hari, D. Annane, M. Bauer, et al., The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (2016) 801-10.http://dx.doi.org/10.1001/jama.2016.0287
[26] S. Gando, M. Levi, and C.H. Toh, Disseminated intravascular coagulation. Nat Rev Dis Primers 2 (2016) 16037.http://dx.doi.org/10.1038/nrdp.2016.37
[27] N. Gupta, Y.Y. Zhao, and C.E. Evans, The stimulation of thrombosis by hypoxia. Thromb Res 181 (2019) 77-83.http://dx.doi.org/10.1016/j.thromres.2019.07.013
[28] I. Paranjpe, V. Fuster, A. Lala, A.J. Russak, B.S. Glicksberg, M.A. Levin, et al., Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol 76 (2020) 122-124.http://dx.doi.org/10.1016/j.jacc.2020.05.001
[29] S. Schulman, S. Konstantinides, Y. Hu, and L.V. Tang, Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. Thromb Haemost 120 (2020) 1143-1146.http://dx.doi.org/10.1055/s-0040-1712913
[30] L. Shen, L. Qiu, D. Liu, L. Wang, H. Huang, H. Ge, et al., The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19. Cardiovasc Drugs Ther (2021).http://dx.doi.org/10.1007/s10557-020-07133-3
[31] A.F. Di Castelnuovo, S. Costanzo, and L. Iacoviello, Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study. Thromb Haemost (2021).http://dx.doi.org/10.1055/a-1347-6070
[32] E.L. Evans, O.V. Povstyan, D. De Vecchis, F. Macrae, L. Lichtenstein, T.S. Futers, et al., Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. Blood 136 (2020) 140-144.http://dx.doi.org/10.1182/blood.2019004174
[33] V.K. Somers, T. Kara, and J. Xie, Progressive Hypoxia: A Pivotal Pathophysiologic Mechanism of COVID-19 Pneumonia. Mayo Clin Proc 95 (2020) 2339-2342.http://dx.doi.org/10.1016/j.mayocp.2020.09.015
[34] J. Xie, N. Covassin, Z. Fan, P. Singh, W. Gao, G. Li, et al., Association Between Hypoxemia and Mortality in Patients With COVID-19. Mayo Clin Proc 95 (2020) 1138-1147.http://dx.doi.org/10.1016/j.mayocp.2020.04.006
[35] G. Grasselli, A. Zangrillo, A. Zanella, M. Antonelli, L. Cabrini, A. Castelli, et al., Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323 (2020) 1574-1581.http://dx.doi.org/10.1001/jama.2020.5394
[36] C. Ferrando, F. Suarez-Sipmann, R. Mellado-Artigas, M. Hernandez, A. Gea, E. Arruti, et al., Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med 46 (2020) 2200-2211.http://dx.doi.org/10.1007/s00134-020-06192-2
[37] E. Nicastri, N. Petrosillo, T. Ascoli Bartoli, L. Lepore, A. Mondi, F. Palmieri, et al., National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep 12 (2020) 8543.http://dx.doi.org/10.4081/idr.2020.8543